Baidu
map

Oncogene:一种新的潜在的抗癌靶点EMI1被发现

2016-06-05 佚名 生物谷

图片来源:medicalxpress.com 近日,刊登在国际杂志Oncogene上题为“In vivo overexpression of Emi1 promotes chromosome instability and tumorigenesis”的一项研究报告中,来自昆士兰大学的研究人员通过研究发现了引发大多数癌症发生的关键驱动子,这些癌症包括乳腺癌、肺癌、肝癌及卵巢癌等。研究者表示,

图片来源:medicalxpress.com

近日,刊登在国际杂志Oncogene上题为“In vivo overexpression of Emi1 promotes chromosome instability and tumorigenesis”的一项研究报告中,来自昆士兰大学的研究人员通过研究发现了引发大多数癌症发生的关键驱动子,这些癌症包括乳腺癌、肺癌、肝癌及卵巢癌等。研究者表示,本文研究发现为后期开发改善癌症诊断的技术、治疗癌症的新型疗法提供了新的思路和研究基础。

Pascal Duijf博士指出,我们在来自胶质母细胞瘤及骨癌的肿瘤样本中发现较高水平的EMI1蛋白;而高水平的EMI1蛋白往往会促进肿瘤发展,增加肿瘤扩散的趋势并且改变机体中免疫反应进而促进肿瘤不断恶化;同时研究者还指出,高水平的EMI1蛋白往往和癌症患者的预后较差直接相关。

研究者认为,高水平的EMI1蛋白会干扰正常细胞的分裂,致使细胞最终分裂成为携带异常染色体数目的新细胞;这种不稳定的细胞分裂过程称之为染色体不稳定性,该过程会加速癌症恶化并且促进肿瘤细胞对癌症疗法产生耐受性。同样,高水平的EMI1蛋白也是指示染色体不稳定性的指示器。

最后研究者Duijf指出,本文研究发现距离开发新型癌症疗法又迈进了一步,下一步我们将会进行更为深入的研究来确定是否肿瘤会维持高水平的EMI1蛋白得以生存,如果真是这样的话,那么我们或许就会以EMI1蛋白为靶点来开发新型的个体化癌症疗法。

原始出处

S Vaidyanathan, K Cato, L Tang, S Pavey, N K Haass, B G Gabrielli and P H G Duijf .In vivo overexpression of Emi1 promotes chromosome instability and tumorigenesis.Oncogene.2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2048712, encodeId=80172048e120b, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Nov 10 22:16:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558040, encodeId=9ae5155804010, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88767, encodeId=421e88e6742, content=这个厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:06:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88768, encodeId=e80b88e6857, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:06:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88769, encodeId=e06e88e6954, content=精品文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=215, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:06:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88604, encodeId=ba8288604a0, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:04:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
    2016-11-10 cy0324
  2. [GetPortalCommentsPageByObjectIdResponse(id=2048712, encodeId=80172048e120b, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Nov 10 22:16:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558040, encodeId=9ae5155804010, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88767, encodeId=421e88e6742, content=这个厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:06:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88768, encodeId=e80b88e6857, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:06:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88769, encodeId=e06e88e6954, content=精品文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=215, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:06:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88604, encodeId=ba8288604a0, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:04:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
    2016-06-07 zsyan
  3. [GetPortalCommentsPageByObjectIdResponse(id=2048712, encodeId=80172048e120b, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Nov 10 22:16:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558040, encodeId=9ae5155804010, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88767, encodeId=421e88e6742, content=这个厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:06:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88768, encodeId=e80b88e6857, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:06:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88769, encodeId=e06e88e6954, content=精品文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=215, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:06:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88604, encodeId=ba8288604a0, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:04:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
    2016-06-06 milkshark

    这个厉害

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2048712, encodeId=80172048e120b, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Nov 10 22:16:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558040, encodeId=9ae5155804010, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88767, encodeId=421e88e6742, content=这个厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:06:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88768, encodeId=e80b88e6857, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:06:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88769, encodeId=e06e88e6954, content=精品文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=215, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:06:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88604, encodeId=ba8288604a0, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:04:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
    2016-06-06 milkshark

    值得学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2048712, encodeId=80172048e120b, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Nov 10 22:16:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558040, encodeId=9ae5155804010, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88767, encodeId=421e88e6742, content=这个厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:06:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88768, encodeId=e80b88e6857, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:06:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88769, encodeId=e06e88e6954, content=精品文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=215, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:06:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88604, encodeId=ba8288604a0, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:04:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
    2016-06-06 milkshark

    精品文章

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2048712, encodeId=80172048e120b, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Nov 10 22:16:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558040, encodeId=9ae5155804010, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88767, encodeId=421e88e6742, content=这个厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:06:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88768, encodeId=e80b88e6857, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:06:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88769, encodeId=e06e88e6954, content=精品文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=215, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:06:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88604, encodeId=ba8288604a0, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:04:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
    2016-06-05 沉心多思

    不错的文章,多学习

    0

相关资讯

Cancer Cell:化学修饰糖尿病治疗药物 摇身变成抗癌“小能手”

本文亮点: HA15是一种特异性靶向BiP/GRP78/HSPA5的分子 HA15诱导内质网应激导致癌细胞死亡,这种情况在体内体外都存在 HA15能够克服黑色素瘤对BRAF抑制剂的抵抗作用 HA15是治疗黑色素瘤的一种潜在方法 近日,来自法国的科学家在国际学术期刊Cancer Cell上发表了一项最新研究进展,他们发现了一种新分子能够有效杀伤黑色素瘤细胞,同时还可以克服黑色素瘤细胞对

科技进步赶不上淘宝造假——青蒿素抗癌药“被研发”了

原标题:网店称青蒿素保健品能抗癌 专家称没有明确定论  随着屠呦呦女士获得诺贝尔医学奖,青蒿素开始走入大众的视野,与此同时,网络购物平台上开始出现一些青蒿素产品。日前,北京青年报记者在互联网上检索“青蒿素保健品”时发现,有多家网店在出售国外进口的高纯度青蒿素保健品,其中有不少商家在介绍该产品时称其能够“抗癌、抗肿瘤、治疗白血病”。相关专家表示,青蒿素是否有抗癌作用尚在研究中,还没有

十字花科蔬菜抗癌作用大揭密,今天你吃了吗?

高压快节奏生活之下,身体健康显得愈发宝贵。如何高效方便地保持身体健康,是现代人关注的重中之重。注意饮食和坚持运动是医生反复强调的答案,其中,避免摄入过高热量的同时保证充足的营养,是重要一环。吃什么、怎么吃,是门大学问。任何一个国家的膳食指南都无一例外地指出要保证蔬菜的摄入量。而在各种颜色、各种优秀的蔬菜中,唯有十字花科蔬菜被冠以“抗癌天使”的美誉。果真有说得那么好吗?萝卜硫素减缓乳癌十字花科,顾名

世界癌症日:10种健康生活方式 远离癌症

世界癌症日是由国际抗癌联盟(UICC)于2000年发起,活动时间定于每年的2月4日。2016年的活动主题定为:“我们能,我能战胜癌症(WECAN,ICAN)”。旨在通过全球范围的宣传活动,帮助公众消除对癌症的错误认知,引导公众养成健康的生活方式,提高癌症早诊水平,降低癌症发病率;对癌症患者要加强康复指导、心理关怀,帮助患者重找社会角色,提高患者生活质量。 随着医学技术的发展,癌症已成

奥巴马设立抗癌“登月计划”特别小组

新华社华盛顿1月28日电(记者林小春)美国总统奥巴马28日签署总统备忘录,设立一个抗击癌症的特别小组,这是奥巴马政府为推动抗癌“登月计划”迈出的第一步。 特别小组全名为“白宫抗癌登月计划特别小组”,由副总统拜登主导负责,成员包括国防部、商务部、卫生与公众服务部、能源部、国家卫生研究院、国家癌症研究所等13个政府机构的高级官员。该特别小组将在今年12月31日前向奥巴马提交一份相关报告。

Lancet Oncol:18个发达国家抗癌药物价格分析

 癌症是全球范围内发病率和死亡率的主要原因,尤其是在高收入国家。即便是在欧洲发达国家,癌症的治疗仍然是一大公共卫生挑战。癌症药物普遍很昂贵。目前仍没有多国性的癌症药物价格对比研究。因此世界卫生组织试图来调查、分析高收入国家的癌症药物价格情况。 此项研究包含了18个发达国家,其中16个是欧洲过去,另外两个是澳大利亚和新西兰。研究人员收集了2013年6月份31种癌症药物的出厂价格。

Baidu
map
Baidu
map
Baidu
map